University of Colorado
Anschutz Medical Campus

Institutional Biosafety Committee (IBC)
Zoom Meeting Minutes
24 August 2026
9:00-11:00am (Mountain Time)

Attendance:

Voting IBC Members:

[redacted] (JA)
Dr. [redacted] (EC)
Dr. [redacted] (HD)
Dr. [redacted] (PD)
Dr. [redacted] (MF)
Dr. [redacted] (LH)
Dr. [redacted] (BH)
[redacted] (EK)
Dr. [redacted] (SK)
Dr. [redacted] (AL)
Dr. [redacted] (CM)
[redacted] (SM)*
Dr. [redacted] (Co-chair) (TM)
[redacted] (JR)
Dr. [redacted] (MV)
[redacted] (ZJW)

Non-voting IBC Members/Guests:

[redacted] (AA)
[redacted] (JH)**
[redacted] (JW)
[redacted] (CW)**

I. **Call to Order:** 9:01am (Mountain Time)

II. **Conflict of Interest:**
- All present IBC members were reminded that no member of an IBC may be involved (except to provide information requested by the IBC) in the review of approval of a project in which he/she/they have been or expect(s) to have a conflict of interest—including financial interests, personal relationships, or involvement in the research. Any committee member with a conflict of interest shall abstain from the vote.

III. **Review and Approval of Previous Minutes:** 27 July 2026
The minutes were reviewed and approved by the IBC.
Approved = 10
Opposed = 0
Abstained = 5 (EC, TM, CM, PD, and AL)

IV. **IBC Administrative Business:**
1. **IBC Administrative Changes:** None
2. **Protocol Closures:**
   a. [redacted] - # 1252
3. **Protocol Transfers:** None

Recombinant and/or Synthetic Nucleic Acid Molecules Research Applications Review:
During the review, the IBC assessed the containment levels in addition to the facilities, procedures, practices, training, and expertise of the laboratory personnel involved in recombinant and/or synthetic nucleic acid molecules research. Additionally, the IBC reviewed agent characteristics, types of manipulations planned, sources of the inserted nucleic acid sequences,

the nature of the inserted nucleic acid sequences, and whether an attempt will be made to obtain expression of a foreign gene, and, if so, the protein that will be produced. The Principal Investigator must determine the applicable section(s) of the *NIH Guidelines*.

V. New Business:

1. **Environmental Health and Safety Office Updates:** None
2. **Biosafety Office Updates:**
    a. BH announced and briefly detailed the *United States Government Policy for Stopping High-Risk Life Sciences Research*
    b. BH announced and briefly detailed the *NIH Biosafety Policy for Research Involving Biohazards* draft and open comment period for replacing the *NIH Guidelines* once approved

VI. Clinical Trial (Human Gene Transfer) Amendments and Notices:

1. Kamdar, Manali - # 21-2578: *Phase 1/1b Study of Bispecific CD19 and CD22 Chimeric Antigen Receptor Co-Expressing T Cells (CD19x22 CAR T) in Adolescent and Adult Patients with Relapsed and/or Refractory B-Non-Hodgkin's Lymphoma (B-NHL)*
2. Kukreja, Janet - # 21-4846: *A Phase 3 Study of CG0070 in Patients with Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)*
3. Moreland, Larry - # 22-1353: *A phase 1 study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Activity of Single Ascending Doses of SBT777101 in Subjects with Rheumatoid Arthritis*
4. Knupp, Kelly - # 25-2098: *ENDEAVOR: A Clinical Study to Evaluate the Safety and Efficacy of ETX101, an AAV9-Delivered Gene Therapy in Infants and Children with SCN1A-positive Dravet Syndrome*
5. Wolf, Andrew - # 25-2749: *A Phase 1/2a, Open-Label, Dose-Escalation Study to Evaluate the Safety and Preliminary Efficacy of TRX319 in Subjects with Primary or Secondary Progressive Multiple Sclerosis*

*SM joined the meeting at 9:05am.

VII. Clinical Trial (Human Gene Transfer) Protocol Reviews:

1. [redacted] **- # 26-1029: A Phase 1/2 Open-Label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, and Efficacy of Intracerebroventricular Administration of LTS-101 in Children with CLN2 Disease**
   Biosafety level: BSL-1
   NIH Section(s): III-C
   Approved = 16
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications required to address contradictions and SOPs regarding viral shedding and excrement management.

2. [redacted] **- # 26-1214: A Phase III, Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, Compared with continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5)**
   Biosafety level: BSL-2
   NIH Section(s): III-C

Approved = 14
Opposed = 0
Abstained = 2 (HD and ZJW)
The IBC protocol presented was approved with no further committee concerns.

**JH and CW left the meeting at 9:30am.

VIII. New Laboratory Protocol Reviews: None

IX. De Novo Laboratory Protocol Reviews:

1. [redacted] **- # 1116: Neural interface technology drives structural and functional plasticity**
   Biosafety level: BSL-1, BSL-2, ABSL-1
   NIH Section(s): III-D-4-a, III-E-1, III-F
   Approved = 16
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including adding details to the research narrative, updating checkboxes for animal tissue use, updating risk group designations, updating rDNA product descriptions, and clarifying BSC details.

2. [redacted] **- # 1159: Circuit mechanisms of motor control**
   Biosafety level: BSL-1, BSL-2, ABSL-1, ABSL-2
   NIH Section(s): III-D-1, III-D-2, III-D-4, III-F
   Approved = 16
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications required to address adding biomaterial procedures, selecting correct IBC protocol checkboxes, updating BSC details for consistency, and adding use of proper engineering controls.

3. [redacted] **- # 1243: Animal and cellular models to identify proteome differences in aging and diseased hearts**
   Biosafety level: BSL-1, BSL-2, ABSL-1
   NIH Section(s): III-D-1, III-D-2, III-F
   Approved = 16
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including adding recombinant product details.

4. [redacted] **- # 1435: Phenotypic characterization of middle ears of A2ml1- and Muc5b-mutant mice**
   Biosafety level: BSL-2, ABSL-2
   NIH Section(s): III-D-4, III-F
   Approved = 16
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation for modifications

required to address updating infectious agent details, adding micro/infectious agent details, and clarifying the BSL for animal studies.

5. [redacted] **- # 1467: Host-Microbiota Studies**
Biosafety level: BSL-2
NIH Section(s): III-D-2, III-F
Approved = 16
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address updating research narrative details, removing outdated IBC protocol details, and updating micro/infectious agent details as needed.

*SM left the meeting at 10:01am.

6. [redacted] **- # 1468: Molecular mechanisms of excitatory and inhibitory synapse cross-talk in plasticity and pathology**
Biosafety level: BSL-1, BSL-2, ABSL-1
NIH Section(s): III-D-1, III-D-2, III-E-1, III-F
Approved = 15
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address adding details in the research narrative, updating agent concentration details, adding plasmid descriptions, and providing consistency regarding live animal work.

7. [redacted] **- # 1473: Capillary control of cerebral blood flow, and its disruption in small vessel disease.**
Biosafety level: BSL-1, ABSL-1
NIH Section(s): III-D-4, III-E-1, III-F
Approved = 15
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address simplifying research narrative details to be more concise and appropriate, adding cell and plasmid use details, selecting appropriate engineering controls, updating procedure details, and adding micro/infectious agent details.

8. [redacted] **- # 1486: Characterization of Genetic Mutations that Cause Human Immune Disease**
Biosafety level: BSL-1, BSL-2, ABSL-1
NIH Section(s): III-D-1, III-D-2, III-D-3, III-E-1, III-E-3, III-F
Approved = 15
Opposed = 0
Abstained = 0
The IBC protocol presented was approved with the recommendation for modifications required to address updating the IBC protocol form for clarity, updating rDNA procedure and micro/infectious agent details, adding downstream procedure details, clarifying use of cells and transgenic animal work, updating IBC protocol checkboxes, and modifying *NIH Guidelines* checkboxes as needed.

9. [redacted] **- # 1635: Electrophysiological studies of specific brain circuits.**
   Biosafety level: BSL-2, ABSL-2
   NIH Section(s): III-D-4, III-F
   Approved = 15
   Opposed = 0
   Abstained = 0
   The IBC protocol presented was approved with the recommendation to address minor administrative items including clarifying use of transgenic animals, updating research narrative details, clarifying BSL discrepancies and use of agents, and updating BSC certification dates.

X. Significant Amendment Reviews for Laboratory Protocols: None

XI. Exempt Protocols – New/Renewal:

1. [redacted] - # 1155: *Inflammatory Drivers of Lung injury, Acute Respiratory Distress Syndrome, Oxygen Toxicity and Resistance, Obesity, Traumatic Brain Injury, Cognitive Function, Aging and Drug Development.*
2. [redacted] - # 1253: *Mechanisms of Acid-sensing ion channel function*
3. [redacted] - # 1478: *Wet laboratory for NMR sample preparation*
4. [redacted] - # 1781: *Houghton Lab human cancer cell line*

XII. Exempt Protocol Amendments:

1. [redacted] - # 1385: *Molecular analyses of vertebrate neurogenesis*
2. [redacted] - # 1626: *Mechanisms of cellular self-renewal*

XIII. Additional Business: None

XIV. Next Meeting Scheduled: 28 September 2026, 9:00am (Mountain Time)

XV. Adjournment: 10:25am (Mountain Time)